Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00154063 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of E2007 in Migraine Prophylaxis
A Phase 2 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 206
- Enrollment target
NCT00154063 is a Phase 2 study that has completed, run by Eisai. The registered enrollment target is 206 participants.
The verdict
NCT00154063, a Phase 2 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 206 participants
- Enrollment target
Study Summary
This was a 22-week, prospective, randomized, double-blind, placebo-controlled, multicenter, parallel-group study that included a 4-week Baseline Phase at the beginning and a 4-week single-blind placebo Safety Phase at the end of the study.
Interventions
- OTHER Placebo
- DRUG E2007
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2005-01 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00154063
The ClinicalTrials.gov registry entry for NCT00154063 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 206 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00154063 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00154063 about?
NCT00154063 is a clinical study titled "Efficacy and Safety Study of E2007 in Migraine Prophylaxis". This was a 22-week, prospective, randomized, double-blind, placebo-controlled, multicenter, parallel-group study that included a 4-week Baseline Phase at the beginning and a 4-week single-blind placebo Safety Phase at the end of the study.
What is the current status of trial NCT00154063?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 206 participants. The study started on 2005-01. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00154063?
The interventions under investigation include: Placebo (OTHER), E2007 (DRUG).
Who is sponsoring clinical trial NCT00154063?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.